BIOGEN INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 236.7 USD | +1.14% |
|
+10.41% | -8.52% |
| 09:16am | Novartis and others face Italy antitrust probe over eye drug | RE |
| Jun. 05 | Transcript : Biogen Inc. Presents at Jefferies 2024 Global Healthcare Conference, Jun-05-2024 12:30 PM |
Financials (USD)
| Sales 2024 * | 9.52B | Sales 2025 * | 9.56B | Capitalization | 34.47B |
|---|---|---|---|---|---|
| Net income 2024 * | 1.94B | Net income 2025 * | 2.26B | EV / Sales 2024 * | 3.93 x |
| Net Debt 2024 * | 2.99B | Net Debt 2025 * | 614M | EV / Sales 2025 * | 3.67 x |
| P/E ratio 2024 * |
18.3
x | P/E ratio 2025 * |
15.7
x | Employees | 7,570 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 85.81% |
More Fundamentals
* Assessed data
More news
Latest transcript on Biogen Inc.
More recommendations
More press releases
More news
| 1 day | +1.14% | ||
| 1 week | +10.41% | ||
| Current month | +5.24% | ||
| 1 month | +8.83% | ||
| 3 months | +8.97% | ||
| 6 months | +3.11% | ||
| Current year | -8.52% |
1 week
218.03
237.54
1 month
210.33237.54
Current year
189.44268.30
1 year
189.44319.76
3 years
187.16468.55
5 years
187.16468.55
10 years
187.16480.18
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 64 | 22-11-13 | |
| Director of Finance/CFO | 60 | 20-08-14 | |
Nicole Murphy
COO | Chief Operating Officer | - | 14-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Stephen Sherwin
BRD | Director/Board Member | 75 | 09-12-31 |
William Hawkins
BRD | Director/Board Member | 70 | 19-06-18 |
Caroline Dorsa
CHM | Chairman | 64 | 10-01-02 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 4.30% | 1 M€ | -1.33% | - | |
| 3.92% | 0 M€ | 0.00% | - | |
| 3.75% | 0 M€ | 0.00% | - | |
| 2.39% | 13,519 M€ | +4.08% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-05 | 236.7 | +1.11% | 947,930 |
| 24-06-04 | 234.1 | +1.88% | 1,016,693 |
| 24-06-03 | 229.8 | +2.16% | 1,220,813 |
| 24-05-31 | 224.9 | +2.21% | 1,872,380 |
| 24-05-30 | 220.1 | +2.64% | 939,978 |
Delayed Quote Nasdaq, June 05, 2024 at 04:00 pm EDT
More quotes
Biogen Inc. is one of the world's leaders in the design, manufacturing, and marketing of therapeutic products. Net sales break down by source of income as follows:
- sales of medicines (73,7%): for treating multiple sclerosis, chronic psoriasis in adults, rheumatoid arthritis, cancers, etc.;
- royalties (17,2%) ;
- other (9,1%): primarily revenues from partnership agreements.
Sector
Pharmaceuticals
Calendar
2024-06-20
- Annual General Meeting
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
BUY
Number of Analysts
34
Last Close Price
236.7
USD
Average target price
284.8
USD
Spread / Average Target
+20.30%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -8.52% | 34.47B | |
| +0.99% | 91.72B | |
| 0.00% | 39.44B | |
| +65.02% | 26.7B | |
| -17.37% | 15.13B | |
| -5.99% | 13.27B | |
| -10.69% | 11.74B | |
| -47.78% | 10.54B | |
| +8.09% | 9.41B | |
| +141.62% | 9.22B |
- Stock Market
- Equities
- BIIB Stock
